Foley Hoag LLP represented Vergent Bioscience
, Inc. (“Vergent”), a clinical-stage biotechnology company developing tumor-targeted imaging agents, in a $21.5 million Series B financing. Vergent will use the funds to advance clinical development of VGT-309, the company’s targeted fluorescent imaging agent that enables surgeons to see previously undetected or difficult-to-find tumors in real time, ensuring all tumor tissue is removed during open, minimally invasive (MIS) and robotic-assisted surgical procedures.
Vergent Bioscience helps surgeons realize the full potential of minimally invasive and robotic surgery by significantly improving the visibility of tumors. The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Foley Hoag attorneys Jeffrey Quillen, Sara Mattern, Kevin Lin and Ivanna Bihun represented Vergent in the financing.